COMMUNIQUÉ DE PRESSE
News
-
-
-
COMMUNIQUÉ DE PRESSE
Transaction Update
Arix Bioscience PLC (ARIX) announces the recommended all-share acquisition of its assets by RTW Biotech Opportunities Ltd. The timetable for the scheme remains as set out in the shareholder circular, with the second general meeting to be held on 12 February 2024 in London, United Kingdom -
COMMUNIQUÉ DE PRESSE
Results of First General Meeting
Arix Bioscience PLC announces results of the first general meeting and the passing of a special resolution to approve the recommended all-share acquisition by RTW Biotech Opportunities Ltd. The second general meeting is scheduled for 12 February 2024 -
COMMUNIQUÉ DE PRESSE
Holding(s) in Company
Arix Bioscience PLC (ARIX) has announced that Acacia Research Corporation, through its subsidiary Merton Acquisition Holdco LLC, has crossed the threshold of voting rights in the company. This notification is in accordance with the TR-1 standard form for notification of major holdings. -
COMMUNIQUÉ DE PRESSE
Holding(s) in Company
Arix Bioscience PLC (ARIX) has received a notification of major holdings from RTW Investments, LP, and RTW Biotech Opportunities Operating Ltd, indicating an increase to a 25.52% stake in the company. The notification was received on 17/01/2024 and comprises 33,023,210 voting rights. -
COMMUNIQUÉ DE PRESSE
Update on the Scheme and Resignation of Directors
Arix Bioscience PLC provides an update on the recommended all-share acquisition of Arix's assets by RTW Biotech Opportunities Ltd, including the resignation of directors Maureen O'Connell and Isaac Kohlberg. The Scheme's condition related to the Share Purchase has been satisfied, and Arix expects to publish the Shareholder circular later this week. -
-
COMMUNIQUÉ DE PRESSE
PDMR Notification & Director Shareholding
-
COMMUNIQUÉ DE PRESSE
Unaudited NAV for October 2023
